by | Dec 20, 2022 | Uncategorized
NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses noteworthy research on early-relapse multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.In one study, isatuximab plus carfilzomib and dexamethasone (Isa-Kd)...
by | Dec 20, 2022 | Uncategorized
NEW ORLEANS — In this video, Samer Al Hadidi, MD, MS, FACP, discusses an analysis of access to chimeric antigen receptor T-cell therapy presented at the ASH Annual Meeting and Exposition.”Patients in the real world continue to show responses to this product, but...
by | Dec 19, 2022 | Uncategorized
NEW ORLEANS — The addition of daratumumab to lenalidomide and dexamethasone continued to benefit transplant-ineligible patients with newly diagnosed multiple myeloma, according to updated results of the randomized phase 3 MAIA study.The daratumumab (Darzalex, Janssen)...
by | Dec 12, 2022 | Uncategorized
Source: Cure Today articles CURE®’s Multiple Myeloma Heroes® Award Program honors and gives thanks to those who have made it their mission to change the lives of patients with multiple myeloma. Read More
by | Dec 12, 2022 | Uncategorized
NEW ORLEANS — Adding daratumumab to bortezomib, lenalidomide and dexamethasone led to improved health-related quality of life for transplant-eligible patients with newly diagnosed multiple myeloma, study results showed.The findings, presented at ASH Annual Meeting and...
by | Dec 12, 2022 | Uncategorized
NEW ORLEANS — Idecabtagene vicleucel induced initial complete remission in nearly half of patients with multiple myeloma who had early relapse after front-line therapy, results of a cohort analysis of the phase 2 KarMMa-2 trial showed.Investigators noted a median...
